Dyne Therapeutics Reports $334.3 Million Net Loss and Increased R&D Expenses for Nine Months Ended September 30, 2025

Dyne Therapeutics, Inc. reported a net loss of $334.3 million for the nine months ended September 30, 2025, compared to a net loss of $227.9 million for the same period in 2024. The company's total operating expenses increased to $352.1 million from $246.8 million year-over-year, driven primarily by a significant rise in research and development costs, which surged to $302.9 million from $199.6 million. The increase in R&D expenses was largely attributed to heightened manufacturing activities and clinical trial costs associated with its product candidates, particularly z-basivarsen and z-rostudirsen.

In terms of financial position, Dyne Therapeutics reported total assets of $867.1 million as of September 30, 2025, up from $691.2 million at the end of 2024. The company’s cash and cash equivalents increased to $573.6 million from $435.4 million, bolstered by capital raised through public offerings and a loan agreement with Hercules Capital, which provided $100 million in initial term loans. The company’s long-term debt stood at $99.1 million as of the reporting date, reflecting its recent borrowing activities.

Operationally, Dyne Therapeutics is advancing its clinical programs, with z-basivarsen currently in a Phase 1/2 clinical trial and z-rostudirsen in a similar stage. The company has initiated a registrational expansion cohort for z-basivarsen, aiming for full enrollment by early Q2 2026, with potential FDA submission for Accelerated Approval planned for Q3 2027. The company also reported positive long-term efficacy and safety data from its trials, which it believes supports the clinical benefit of its product candidates.

The company’s workforce has expanded, contributing to increased general and administrative expenses, which rose to $49.2 million from $47.2 million year-over-year. As of September 30, 2025, Dyne Therapeutics had 142.6 million shares outstanding, reflecting its capital-raising efforts. Looking ahead, the company anticipates continued operating losses and significant expenses as it progresses its clinical development and seeks regulatory approvals. Dyne Therapeutics expects its existing cash and marketable securities to fund operations into the third quarter of 2027, contingent on successful clinical outcomes and regulatory approvals.